当前位置： SCI文献检索 > CANCER GENE THERAPY期刊下所有文献 > Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts.

Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts.

Abstract：

:We have developed unique replication-competent retroviral (RCR) vectors based on murine leukemia virus that provide improved efficiency of viral delivery, allow for long-term transgene expression and demonstrate an intrinsic selectivity for transduction of rapidly dividing tumor cells. The purpose of this study was to evaluate the in vivo transduction efficiency and the therapeutic efficacy of the RCR vector mediated delivery of Escherichia coli purine nucleoside phosphorylase (PNP) in combination with fludarabine phosphate for bladder cancer. We constructed vectors containing green fluorescent protein (GFP) gene (ACE)-GFP) or PNP gene (ACE-PNP). KU-19-19 bladder tumors exhibited 28.3+/-16.1, 46.6+/-5.8 and 93.7+/-7.8% of GFP expression on 14, 18 and 26 days after intratumoral injection of ACE-GFP, respectively. GFP expression could not be observed in normal tissues surrounding the injected tumors. No detectable polymerase chain reaction products of GFP gene could be observed in any distant organs. Intratumoral injection of ACE-PNP, followed by systemically administered fludarabine phosphate, significantly inhibited the growth of pre-established KU-19-19 tumors. Our results indicate that RCR vectors are a potentially efficient gene delivery method and that the RCR vector mediated PNP gene transfer and fludarabine phosphate treatment might be a novel and potentially therapeutic modality for bladder cancer.

journal_name

Cancer Gene Ther

journal_title

Cancer gene therapy

authors

Kikuchi E,Menendez S,Ozu C,Ohori M,Cordon-Cardo C,Logg CR,Kasahara N,Bochner BH

doi

10.1038/sj.cgt.7701013

subject

Has Abstract

pub_date

2007-03-01 00:00:00

pages

279-86

issue

3

eissn

0929-1903

issn

1476-5500

pii

7701013

journal_volume

14

pub_type

杂志文章

相关文献

CANCER GENE THERAPY文献大全
  • Suppressor of cytokine signaling-1 expression by infectivity-enhanced adenoviral vector inhibits IL-6-dependent proliferation of multiple myeloma cells.

    abstract：:Multiple myeloma (MM) accounts for 10% of hematological malignant disorders. Its refractory nature indicates the necessity of developing novel therapeutic modalities. Since interleukin 6 (IL-6) is one of the major growth factors for MM cells, we expressed suppressor of cytokine signaling-1 (SOCS-1), one of the blockad...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700873

    authors： Yamamoto M,Nishimoto N,Davydova J,Kishimoto T,Curiel DT

    更新日期：2006-02-01 00:00:00

  • Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.

    abstract：:Aberrantly expressed microRNAs (miRNAs) are involved in breast tumorigenesis. It is still unclear if and how miRNAs-221/222 are implicated in breast cancer and the resistance to estrogen receptor modulator tamoxifen. We investigated the roles and mechanisms of miR-221/222 in breast cancer cells, particularly in modula...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2014.29

    authors： Gan R,Yang Y,Yang X,Zhao L,Lu J,Meng QH

    更新日期：2014-07-01 00:00:00

  • Papillomaviruses as targets for cancer gene therapy.

    abstract：:The human papillomaviruses (HPVs) are a diverse group of infectious agents, some of which are a causative agent of human cancers. Cervical cancer and oral cancer are closely associated with specific types of HPV, and the tumors grow only if there is continual expression of the viral E6 and E7 genes. Evidence from in v...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/sj.cgt.7700926

    authors： Shillitoe EJ

    更新日期：2006-05-01 00:00:00

  • Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.

    abstract：:T cells can be reprogrammed to redirect specificity to tumor-associated antigens (TAAs) through the enforced expression of chimeric antigen receptors (CARs). The prototypical CAR is a single-chain molecule that docks with TAA expressed on the cell surface and, in contrast to the T-cell receptor complex, recognizes tar...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/cgt.2014.69

    authors： Singh H,Moyes JS,Huls MH,Cooper LJ

    更新日期：2015-03-01 00:00:00

  • Bacterial vectors for imaging and cancer gene therapy: a review.

    abstract：:The significant burden of resistance to conventional anticancer treatments in patients with advanced disease has prompted the need to explore alternative therapeutic strategies. The challenge for oncology researchers is to identify a therapy which is selective for tumors with limited toxicity to normal tissue. Enginee...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/cgt.2012.59

    authors： Cronin M,Stanton RM,Francis KP,Tangney M

    更新日期：2012-11-01 00:00:00

  • Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination.

    abstract：:Most cancer vaccines to date have made use of common tumor antigens or allogenic cancer cell lines. The majority of tumor antigens may, however, be unique patient-specific antigens. Dendritic cells (DCs) are the most potent antigen-presenting cells known. The present report is a full-scale preclinical evaluation of au...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700837

    authors： Kyte JA,Kvalheim G,Aamdal S,Saebøe-Larssen S,Gaudernack G

    更新日期：2005-06-01 00:00:00

  • Locked nucleic acid inhibits miR-92a-3p in human colorectal cancer, induces apoptosis and inhibits cell proliferation.

    abstract：:MicroRNAs (miRNAs) are a type of small noncoding RNAs that have a vital role in basic biological processes such as cellular growth, division and apoptosis. A change in the expression of miRNAs can induce many diseases. Recently, the role of miRNA in some of the cancers as a tumor suppressor and oncogene has been recog...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2016.10

    authors： Ahmadi S,Sharifi M,Salehi R

    更新日期：2016-07-01 00:00:00

  • Role of autophagy in oncolytic herpes simplex virus type 1-induced cell death in squamous cell carcinoma cells.

    abstract：:Herpes simplex virus type 1 (HSV-1) is one of the most widely studied viruses for oncolytic virotherapy. In squamous cell carcinoma (SCC) cells, the role of autophagy induced by neurovirulence gene-deficient HSV-1s in programmed cell death has not yet been elucidated. The oncolytic HSV-1 strain RH2, which lacks the γ3...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2017.33

    authors： Furukawa Y,Takasu A,Yura Y

    更新日期：2017-09-01 00:00:00

  • Zinc fingers and homeoboxes family in human diseases.

    abstract：:The zinc-fingers and homeoboxes (ZHX) family is a group of nuclear homodimeric transcriptional repressors that interact with a subunit of nuclear factor-Y (NF-YA) and contain two C2H2-type zinc fingers and five homeobox DNA-binding domains. The members of ZHX family form homodimers or heterodimers with other members o...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/cgt.2015.16

    authors： Liu Y,Ma D,Ji C

    更新日期：2015-05-01 00:00:00

  • CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research.

    abstract：:Herpes simplex viruses (HSVs) are important pathogens and ideal for gene therapy due to its large genome size. Previous researches on HSVs were hampered because the technology to construct recombinant HSVs were based on DNA homology-dependent repair (HDR) and plaque assay, which are inefficient, laborious, and time-co...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/s41417-018-0016-3

    authors： Wang D,Wang XW,Peng XC,Xiang Y,Song SB,Wang YY,Chen L,Xin VW,Lyu YN,Ji J,Ma ZW,Li CB,Xin HW

    更新日期：2018-06-01 00:00:00

  • Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers.

    abstract：:Poor tumor targeting of oncolytic adenoviruses (OAdv) after systemic administration is considered a major limitation for virotherapy of disseminated cancers. The benefit of using mesenchymal stem cells as cell carriers for OAdv tumor targeting is currently evaluated not only in preclinical models but also in clinical ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-019-0110-1

    authors： Barlabé P,Sostoa J,Fajardo CA,Alemany R,Moreno R

    更新日期：2020-05-01 00:00:00

  • Suppression of the Ewing's sarcoma phenotype by FLI1/ERF repressor hybrids.

    abstract：:Fusion of the 5' half of the Ewing's sarcoma (ES) gene EWS with the DNA-binding domain of several transcription factors has been detected in many human tumors. The t(11;22)(q24;q12) chromosomal translocation is specifically linked to ES and primitive neuroectodermal tumors and results, in the majority of cases, in the...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700220

    authors： Athanasiou M,LeGallic L,Watson DK,Blair DG,Mavrothalassitis G

    更新日期：2000-08-01 00:00:00

  • A multiprong approach to cancer gene therapy by coencapsulated cells.

    abstract：:Immune-isolation of nonautologous cells with microencapsulation protects these cells from graft rejection, thus allowing the same recombinant therapeutic cell line to be implanted in different recipients. This approach was successful in treating HER2/neu-expressing tumors in mice by delivering an interleukin-2 fusion ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700786

    authors： Cirone P,Shen F,Chang PL

    更新日期：2005-04-01 00:00:00

  • Alternative splicing as a novel of means of regulating the expression of therapeutic genes.

    abstract：:In order to determine the potential of alternative splicing as a means of targeting the expression of therapeutic genes to tumor cells in vivo, a series of episomal plasmid-based "splice-activated gene expression" (pSAGE) vectors was generated, which contain minigene cassettes composed of various combinations of the t...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700427

    authors： Hayes GM,Carpenito C,Davis PD,Dougherty ST,Dirks JF,Dougherty GJ

    更新日期：2002-02-01 00:00:00

  • Overexpression of BMP1 reflects poor prognosis in clear cell renal cell carcinoma.

    abstract：:Clear cell renal cell carcinoma (ccRCC) is the highest mortality, invasion, and metastasis subtype of renal cell carcinoma. Bone morphogenetic protein (BMP) family has recently emerged as a group of cancer-related proteins in multiple pathogenesis of cancers. Currently, little is known about the prediction role of BMP...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-019-0107-9

    authors： Xiao W,Wang X,Wang T,Xing J

    更新日期：2020-05-01 00:00:00

  • Calcium-sensing receptor antagonist NPS-2143 suppresses proliferation and invasion of gastric cancer cells.

    abstract：:NPS-2143 is a calcium-sensing receptor (CaSR) antagonist that has been demonstrated to possess anticancer activity. To date, the effects of NPS-2143 on gastric cancer (GC) cell growth, motility, and apoptosis have not been investigated. In the present study, we firstly investigated the expression of CaSR in GC tissues...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-019-0128-4

    authors： Zhang ZL,Li ZR,Li JS,Wang SR

    更新日期：2020-08-01 00:00:00

  • Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours.

    abstract：:Chimeric Antigen Receptor (CAR) T-cell therapy, as an approved treatment option for patients with B cell malignancies, demonstrates that genetic modification of autologous immune cells is an effective anti-cancer regimen. Erythropoietin-producing Hepatocellular receptor tyrosine kinase class A2 (EphA2) is a tumour ass...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-020-00221-4

    authors： Hsu K,Middlemiss S,Saletta F,Gottschalk S,McCowage GB,Kramer B

    更新日期：2020-09-01 00:00:00

  • Correlations of TNF-α gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population.

    abstract：:This study was performed with the aim to investigate the correlations of tumor necrosis factor-alpha (TNF-α) gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis (T-MG) in a northern Chinese Han population. Between June 2005 and June 2015, 305 MG patients (150 males and 155 females, MG gro...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2017.13

    authors： Yang HW,Lei P,Xie YC,Han ZL,Li D,Wang SH,Sun ZL

    更新日期：2017-06-01 00:00:00

  • Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?

    abstract：:MicroRNAs (miRNAs) were discovered more than a decade ago as noncoding, single-stranded small RNAs (approximately 22 nucleotides) that control the timed gene expression pattern in Caenorhabditis elegans life cycle. A number of these evolutionarily conserved, endogenous miRNAs have been shown to regulate mammalian cell...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/cgt.2008.8

    authors： Tong AW,Nemunaitis J

    更新日期：2008-06-01 00:00:00

  • Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.

    abstract：:B-cell malignancies upregulate the B-cell lymphoma 2 (Bcl-2) family inhibitors of the intrinsic apoptosis pathway, making them therapy resistant. However, small-molecule inhibitors of Bcl-2 family members such as ABT-737 restore a functional apoptosis pathway in cancer cells, and its oral analog ABT-263 (Navitoclax) h...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2013.35

    authors： Karlsson H,Lindqvist AC,Fransson M,Paul-Wetterberg G,Nilsson B,Essand M,Nilsson K,Frisk P,Jernberg-Wiklund H,Loskog A

    更新日期：2013-07-01 00:00:00

  • Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.

    abstract：:Gene therapy for prostate cancer may be realized through transduction of whole genes, such as PSA or PSMA, into immunotherapeutic dendritic cells (DCs). An oncoretroviral vector encoding human PSMA and a bicistronic oncoretroviral vector encoding human PSA and cell surface CD25 cDNAs were constructed. Remarkably, tran...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700810

    authors： Medin JA,Liang SB,Hou JW,Kelley LS,Peace DJ,Fowler DH

    更新日期：2005-06-01 00:00:00

  • HJURP knockdown disrupts clonogenic capacity and increases radiation-induced cell death of glioblastoma cells.

    abstract：:The Holliday Junction-Recognition Protein (HJURP) was reported as overexpressed in several cancers and also strongly correlated with poor prognosis of patients, especially in glioblastoma (GBM), the most common and deadly type of primary brain tumor. HJURP is responsible for loading the histone H3 variant-the Centrome...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-019-0103-0

    authors： Serafim RB,Cardoso C,Di Cristofaro LFM,Pienna Soares C,Araújo Silva W Jr,Espreafico EM,Paçó-Larson ML,Price BD,Valente V

    更新日期：2020-05-01 00:00:00

  • Endostatin therapy reveals a U-shaped curve for antitumor activity.

    abstract：:Developing continuous systemic delivery of endostatin has been a goal of many laboratories. We have employed a method of gene therapy utilizing different viral constructs. Here, we report that a new serotype of adeno-associated viruses, which incorporates canine endostatin, provides dose-dependent transgene expression...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700938

    authors： Tjin Tham Sjin RM,Naspinski J,Birsner AE,Li C,Chan R,Lo KM,Gillies S,Zurakowski D,Folkman J,Samulski J,Javaherian K

    更新日期：2006-06-01 00:00:00

  • TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.

    abstract：:Immune checkpoint inhibition (ICI) has revolutionized cancer treatment, and produced durable responses in many cancer types. However, there remains a subset of patients that do not respond despite their tumors exhibiting PD-L1 expression, which highlights the need for additional biomarkers relevant to response. Here, ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/s41417-020-0174-y

    authors： Choucair K,Morand S,Stanbery L,Edelman G,Dworkin L,Nemunaitis J

    更新日期：2020-12-01 00:00:00

  • The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses.

    abstract：:Oncolytic adenoviruses are promising anticancer agents. To study and optimize their tumor-killing potency, genuine tumor models are required. Here we describe the use of the chicken chorioallantoic membrane (CAM) tumor model in studies on oncolytic adenoviral vectors. Suspensions of human melanoma, colorectal carcinom...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2011.68

    authors： Durupt F,Koppers-Lalic D,Balme B,Budel L,Terrier O,Lina B,Thomas L,Hoeben RC,Rosa-Calatrava M

    更新日期：2012-01-01 00:00:00

  • Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.

    abstract：:Replication-selective oncolytic viruses are being developed for human cancer therapy. We previously developed an attenuated adenovirus (OBP-301, Telomelysin), in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site. OBP-301...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2012.57

    authors： Watanabe Y,Hashimoto Y,Kagawa S,Kawamura H,Nagai K,Tanaka N,Urata Y,Fujiwara T

    更新日期：2012-11-01 00:00:00

  • MicroRNA silencing improves the tumor specificity of adenoviral transgene expression.

    abstract：:Adenoviral technology has been thoroughly evaluated for delivering genetic material to tumor tissue and the surrounding microenvironment. Almost any gene can be cloned into an adenovirus (Ad) vector, which when combined with strong, constitutively active promoters permit up to a million-fold amplification of the trans...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2012.16

    authors： Card PB,Hogg RT,Gil Del Alcazar CR,Gerard RD

    更新日期：2012-07-01 00:00:00

  • Complementary adenoviral vectors for oncolysis.

    abstract：:Replication-competent adenoviruses (Ads) were used for oncolytic virotherapy soon after they were discovered. Recently mutated and genetically engineered Ads have been shown to selectively lyse tumor cells. We have split the human Ad type 5 genome into two defective viruses that complement each other only in certain t...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700001

    authors： Alemany R,Lai S,Lou YC,Jan HY,Fang X,Zhang WW

    更新日期：1999-01-01 00:00:00

  • Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor.

    abstract：:Specificity is a prerequisite for systemic gene therapy of hepatocarcinoma. In vitro, the tumor-specific viral death effector Apoptin selectively induces apoptosis in malignant hepatic cells. Intratumoral treatment of xenografted subcutaneous hepatomas with Apoptin results in tumor regression. Here, we report a system...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700985

    authors： Peng DJ,Sun J,Wang YZ,Tian J,Zhang YH,Noteborn MH,Qu S

    更新日期：2007-01-01 00:00:00

  • Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70.

    abstract：:Gene-directed enzyme prodrug therapy (GDEPT) is a promising approach to local management of cancer through targeted chemotherapy. Killing localized tumors by GDEPT in a manner that induces strong antitumor cellular immune responses might improve local management and allow benefit in disseminated cancer. Here we evalua...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700807

    authors： Djeha HA,Todryk SM,Pelech S,Wrighton CJ,Irvine AS,Mountain A,Lipinski KS

    更新日期：2005-06-01 00:00:00